Literature DB >> 27048409

Protective Effects of Danlou Tablet () against Murine Myocardial Ischemia and Reperfusion Injury In Vivo.

Jian-Yong Qi1, Lei Wang1, Dong-Sheng Gu2, Li-Heng Guo1, Wei Zhu3, Min-Zhou Zhang4.   

Abstract

OBJECTIVE: To observe the in vivo effect of Danlou Tablet (, DLT) on myocardial ischemia and reperfusion (I/R) injury.
METHODS: DLT effects were evaluated in mouse heart preparation using 30-min coronary occlusion followed by 24-h reperfusion and compared among sham group (n=6), I/R group (n=8), IPC group (ischemia preconditioning, n=6) and DLT group (I/R with DLT pretreatment for 3 days, 750 mg•kg-1•day-1, n=8). The effects of DLT were characterized in infarction size (IS) compared with risk region (RR) and left ventricle using the Evans blue/triphenyltetrazolium chloride double dye staining method in vivo. Furthermore, the dose-dependent effect of DLT on I/R injury was evaluated by double staining method. Five different concentrations of DLT (0.625, 1.25, 2.5, 5 and 10 g•kg-1•day-1) were chosen in this study, and dose-response curve of DLT was obtained on these data.
RESULTS: The ratio of IS to left ventricle was significantly smaller in the DLT and IPC groups than the I/R group (P<0.05 or P<0.01), the ratio of IS to RR was also reduced in the DLT and IPC groups (P<0.01), while there were no differences in RR among the four groups (P>0.05). Experiments showed incidence of arrhythmias was reduced in the DLT group (P<0.01). Furthermore, DLT produced a dose-dependent inhibitory effect with a half maximal inhibitory concentration of 1.225 g•kg-1•day-1.
CONCLUSIONS: Our research concluded that DLT was effective in reducing I/R injury in mice, and provided experimental supports for the clinical use of DLT.

Entities:  

Keywords:  Chinese medicine; Danlou Tablet; ischemia and reperfusion

Mesh:

Substances:

Year:  2016        PMID: 27048409     DOI: 10.1007/s11655-016-2448-7

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  22 in total

Review 1.  The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.

Authors:  Derek J Hausenloy; Andrew Tsang; Derek M Yellon
Journal:  Trends Cardiovasc Med       Date:  2005-02       Impact factor: 6.677

2.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

3.  Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.

Authors:  Lennart Nilsson; Jonas Hallén; Dan Atar; Lena Jonasson; Eva Swahn
Journal:  Heart       Date:  2011-07-04       Impact factor: 5.994

4.  Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats.

Authors:  Zi-Pu Li; Qian Cao
Journal:  Acta Pharmacol Sin       Date:  2002-10       Impact factor: 6.150

5.  Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase.

Authors:  Xiao-Le Xu; Xiang-Jian Chen; Hui Ji; Ping Li; Yun-Yun Bian; Di Yang; Jin-Dan Xu; Zhi-Ping Bian; Ji-Nan Zhang
Journal:  Pharmacology       Date:  2008-03-18       Impact factor: 2.547

6.  Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation.

Authors:  Ying Yin; Yue Guan; Jialin Duan; Guo Wei; Yanrong Zhu; Wei Quan; Chao Guo; Dan Zhou; Yanhua Wang; Miaomiao Xi; Aidong Wen
Journal:  Eur J Pharmacol       Date:  2012-11-29       Impact factor: 4.432

7.  [Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablet].

Authors:  Shi-han Wang; Jie Wang; Ji Li
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2012-08

8.  Long-term results of stent graft treatment of subclavian artery injuries: management of choice for stable patients?

Authors:  Daniel F du Toit; Anton V Lambrechts; Hugo Stark; Brian L Warren
Journal:  J Vasc Surg       Date:  2008-02-01       Impact factor: 4.268

9.  Tongguan Capsule Protects against Myocardial Ischemia and Reperfusion Injury in Mice.

Authors:  Jianyong Qi; Juan Yu; Lei Wang; Liheng Guo; Shiyu Ma; Donghui Huang; Miao Zhou; Jiashin Wu; Minzhou Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-01       Impact factor: 2.629

10.  Apocynum Tablet Protects against Cardiac Hypertrophy via Inhibiting AKT and ERK1/2 Phosphorylation after Pressure Overload.

Authors:  Jianyong Qi; Qin Liu; Kaizheng Gong; Juan Yu; Lei Wang; Liheng Guo; Miao Zhou; Jiashin Wu; Minzhou Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-29       Impact factor: 2.629

View more
  6 in total

1.  Traditional Chinese medicine for acute coronary syndrome: A meta-analysis of clinical manifestations and objective indicators.

Authors:  Jiangquan Liao; Tao Li; Yingying Hua; Mingjing Shao; Yan Wang; Zhe Wang; Kangkang Wei; Jiangmeng Chang; Xiaoqiong Zhang; Ming Chen; Xianlun Li; Jinhang Du
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

2.  Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial.

Authors:  Lei Wang; Xujie Zhao; Shuai Mao; Shaonan Liu; Xinfeng Guo; Liheng Guo; Tinghai Du; Haiyu Yang; Fuhai Zhao; Keng Wu; Hongliang Cong; Yang Wu; Phillip C Yang; Keji Chen; Minzhou Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-08       Impact factor: 2.629

3.  Protective Mechanisms of Suxiao Jiuxin Pills () on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro.

Authors:  Ya-Fang Tan; Juan Yu; Wen-Jun Pan; Jian-Yong Qi; Min-Zhou Zhang
Journal:  Chin J Integr Med       Date:  2020-06-10       Impact factor: 1.978

4.  PPARγ Mediates the Cardioprotective Roles of Danlou Tablet After Acute Myocardial Ischemia-Reperfusion Injury.

Authors:  Meng Wei; Mengying Guo; Xinxiu Meng; Lin Li; Hongyun Wang; Mingxue Zhang; Yihua Bei
Journal:  Front Cardiovasc Med       Date:  2022-03-25

5.  Trichosanthis Pericarpium Aqueous Extract Protects H9c2 Cardiomyocytes from Hypoxia/Reoxygenation Injury by Regulating PI3K/Akt/NO Pathway.

Authors:  Donghai Chu; Zhenqiu Zhang
Journal:  Molecules       Date:  2018-09-20       Impact factor: 4.411

6.  Effects of Danlou tablet for the treatment of stable angina pectoris: A study protocol of a randomized, double-blind, and placebo-controlled clinical trial.

Authors:  Guang Yang; Haoqiang He; Hongzheng Li; Zinuo Shen; Siyuan Zhou; Bingxu Lu; Jun Li; Qingyong He; Zhenpeng Zhang; Yongmei Liu; Jie Wang; Hengwen Chen
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.